Prof James Catto from the University of Sheffield described the findings as a "major breakthrough" in treating bladder cancer ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck ...

According to Bladder Cancer UK, the main symptoms of bladder cancer are: ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

Durvalumab did not improve outcomes compared with cetuximab in patients with head and neck squamous cell carcinoma who are ...

A phase 3 clinical trial has shown that patients were 32 per cent less likely to experience cancer recurrence when treated ...

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...